Ecko

... oscuro independiente del resto del sistema...
Se ha imaginado el mundo sin ciencia?

[Ecko @Ecko4U_]

Calculadora BED con corrección de tiempo....
🙌🏼 https://t.co/K89HbMKFuU

[giuseppe Minniti @gminniti2012]

Interesting question.. using 22.5 Gy/3 for lesions < 1 cm and 27.5/5 > 1 cm we have achieved LC around 81% at 1 year without G3 toxicity. The question is if we can use these dose in combination with systemic treatments (immuno, ADCs)

[ASTRO @ASTRO_org]

New in #practicalRO: Effectiveness of Regional Nodal Irradiation in Women with a Pathologic Complete Response in the Nodes After Neoadjuvant Chemotherapy with Residual Disease in the Breast. https://t.co/gtYT5RRRB3

[Yüksel Ürün @DrYukselUrun]

SBRT to oligometastatic lesions consistently delays ADT, improves PFS, and in some trials cuts biochemical recurrence.
Phase III data is still maturing. Patient selection varies. Imaging definitions differ. @NatRevUrol @OncoAlert @APCCC_Lugano

[Applied Radiation Oncology @Applied_RadOnc]

This study evaluated the effectiveness of a peer-review process to objectively assess the skills of radiation oncology (RO) resident physicians (RPs) in contour grading of head and neck (HN) malignancies.

Learn more 🧠 https://t.co/7qSf1p9I9i

#RadOnc #RadiationOncology #HNC #HeadandNeckCancer #HeadandNeckCancerAwarenessMonth #ResearchArticle #RadOncEd

[NonsparseOncologist @5_utr]

New decision analysis: For rectal cancer patients with complete response after chemoRT, choosing surgery over "Watch & Wait" costs ~9 QALYs - almost a decade of perfect health - lost to permanent toxicity (LARS, sexual dysfunction, stoma)

[Dr Rishabh Jain @DrRishabhOnco]

MRI before prostatectomy isn’t just staging… it’s prognostic.

New meta-analysis in JAMA Oncology shows MRI predicts outcomes independently.

🧵

📌 Study: Pretreatment MRI as prognostic factor after radical prostatectomy
📊 40 studies | 24,941 patients

👨‍⚕️ Population
Men undergoing radical prostatectomy with pre-treatment MRI

⚔️ Key MRI features → Strong outcome predictors

🔴 Extraprostatic extension (mrT3a)
•BCR: HR 2.16
•Metastasis: HR 3.18
•Cancer-specific mortality: HR 10.9 (!!)

🔴 Seminal vesicle invasion (mrT3b)
•BCR: HR 2.74
•Metastasis: HR 5.58

📊 Quantitative MRI also matters
•PI-RADS 4–5 → HR ~2.1
•Tumor ≥20 mm → HR ~2.35
•Low ADC → HR ~2.4

💡 Key insight
MRI adds independent prognostic value beyond PSA, Gleason, and pathology

👉 Not just imaging
👉 A biologic risk signal before surgery

⚠️ Practice-changing angle
MRI T-staging may be stronger than DRE-based clinical staging

→ Enables better pre-op risk stratification
→ Potential for treatment intensification / de-escalation

🎯 Takeaway
If you’re still using MRI only for staging…
You’re underusing it

MRI = prognosis + decision-making tool

🔖 Save this for clinic discussions

📖 Full paper in comment ⬇️

#OncoTwitter #MedTwitter #ProstateCancer #UroOncology @OncoAlert @myesmo @esmo_open @asco

[Adela @adelapoite]

Diagnosis and Management of Resistant Hypertension: A Review | Hypertension | JAMA | JAMA Network https://t.co/Vanp64U37e

[SEOR.es @SEOR_ESP]

El XXIII Congreso Nacional SEOR 2026 contaremos con la participación del Prof. Steven Frank @SJFrankMD en la sesión magistral: Proton Therapy: new paradigm in the treatment of oropharyngeal cancer

Alicante | 📅 3–5 junio 2026

🔗 https://t.co/SYnFPSz5Fc

#SEOR2026 #OncologíaRadioterápica #Protonterapia

[Tyler Seibert - tmp account. Go follow @TylerSbrt @TylerSbrt7]

Let’s talk about prostate and urethra contouring on MRI. Three recent 📄📄📄 @SeibertLab
#radonc #ProstateCancer
🧵1️⃣

@IJROBP @RO_GreenJournal @ARRO_org @ASTRO_org @ESTRO_org

[Advances, an ASTRO Journal @Advances_ASTRO]

📌 Dosimetric Correlates of Acute Toxicities for Moderate Hypofractionated Whole Breast Irradiation: Implications for ASTRO Planning Guidelines ☢️
🔗 https://t.co/zwENRe7nAU
@VishrutaD @JulianaRunnels
@MountSinaiRO @ASTRO_org #BreastCancer #RadOnc
🔸 600 patients treated with HF WBI (42.56 Gy in 16 fractions or 40.05 Gy in 15 fractions) between 2018 and 2023 using 3D conformal field in field planning.
🔹 V105 % (cc) ≥ 50 cc and V105 %(%) ≥ 5% were strong, independent predictors of pain and other grade ≥ 2 toxicities
🔸 Keeping V105%(cc) < 50 cc and V105%(%) < 5% markedly reduced toxicity rates, supporting incorporation of relative dose-volume metrics into future guideline updates.
🔹 Optimizing dose homogeneity remains essential to improving patient comfort and quality of life

[Ecko @Ecko4U_]

"Como los días a tu lado son de fantasía, te doy este totem.
Así siempre sabremos que esta felicidad no es un sueño, sino la realidad que estamos construyendo."

[Jonathan Schoenfeld @jdschoenfeld1]

Excellent commentary on the LU005 results just out in @JCO_ASCO.

💡 Key insights on the optimal timing of ICIs with RT across multiple tumor types, specifically regarding general avoidance of simultaneous initiation of ICI with standard RT.

📊 Includes a high-yield table with results from multiple randomized Ph 2/3 trials and highlights the importance of correlative studies for future combinations.

🔗 Commentary: https://t.co/WLgeD3dMsj

🔗 LU005 Paper: https://t.co/ZnSvy5cb0c

@KatiekeaneMD @AdamJSchoenfeld #RadOnc

[Enséñame de Ciencia @EnsedeCiencia]

Científicos del MIT demostraron que las ondas de WiFi son capaces de detectar personas, posiciones e incluso posturas corporales, sin necesidad de cámaras. 📡

Las señales rebotan en el cuerpo y regresan alteradas, permitiendo que una inteligencia artificial trace siluetas tridimensionales y reconozca posturas humanas con notable exactitud.

Este avance podría revolucionar la atención médica, la seguridad doméstica y la asistencia a personas mayores… pero también despierta un nuevo temor: ¿qué pasará cuando la red que te conecta sea la misma que te observa? 👁️⚡

[Yuan James Rao @yuanjamesrao]

#RadOnc history lesson! The first patient treated with the linear accelerator at Stanford in 1957 (at 2 yrs old) was cured of his cancer, and is still alive (as of 2024). He developed a osteosarcoma in the 1980s and received re-treatment w/ heavy ion RT. Link below for reference.

[Oscar Tahuahua @OscarTahuahua]

In locally advanced rectal cancer, short course RT (25 Gy/5 fx) was less immunosuppressive than long-course RT, despite more advanced disease. SCRT showed faster lymphocyte recovery, lower NLR and higher intratumoral CD8+ and FOXP3+.

This immune preserving profile provides a biological rationale for SCRT-based radio-immunotherapy strategies.
https://t.co/Rfd0Hhd3d0 @OncoAlert

[Dr Rishabh Jain @DrRishabhOnco]

Localised prostate cancer just changed. Again.

ESMO 2026 brings clarity on who to observe, who to escalate, and which trials actually matter 👇

🧠 Diagnosis
MRI before biopsy is standard
High-resolution US is a valid alternative (RCT n=678)

🧭 Low risk
Active surveillance is safe
ProtecT 15-yr data shows similar survival vs RP/RT

☢️ Radiotherapy
Shorter is better
CHHiP ➜ moderate hypofractionation
HYPO-RT-PC ➜ ultra-hypofractionation
PACE-B ➜ SBRT works in selected IR disease

📈 High risk
RT + long-term ADT saves lives
SPCG-7 | NCIC/MRC
Dose escalation improves OS (GETUG-AFU 18)

🚨 Very high-risk / cN1
RT + ADT + abiraterone is the new benchmark
STAMPEDE delivers MFS + OS benefit

🔁 Biochemical recurrence
Avoid routine adjuvant RT
Early salvage RT preferred
RADICALS-RT | RAVES | GETUG-AFU 17
High-risk BCR? Intensify
EMBARK supports enzalutamide + ADT

🧠 Bottom line
Risk-adapted care > overtreatment
Imaging-driven decisions
Escalate only when trials prove benefit

📖 Full paper in comment ⬇️

#OncoTwitter #MedTwitter #ProstateCancer #GUOncology
@OncoAlert @myesmo @esmo_open @asco @OncBrothers

[Felipe Couñago PhD @fcounago]

El sábado compartí esta charla sin expectativas.
Los mensajes recibidos estos días me han recordado algo importante 👇

❌ No va de llegar más alto ⬆️
✅ Va de mantenerse fiel a lo que uno es 🧭

La dejo de nuevo por aquí 👇🎥

https://t.co/xyV6f5fH6H

[Nicholas Zaorsky, MD MS @NicholasZaorsky]

Radiation therapy side effects for prostate cancer: what actually happens (and what doesn't)

https://t.co/QH8zzgn243

[ESTRO @ESTRO_RT]

Salvage metastasis-directed therapy vs elective nodal #radiotherapy for oligorecurrent nodal #prostatecancer metastases (PEACE V-STORM) published in the @TheLancetOncol.
👉 Read it before your patients: https://t.co/eCCQDjSyre
@piet_ost @Mat_Guc